Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company announced. “We are delighted with the news of the preliminary results of the Phase III confirmatory study of our proprietary…
The European Commission has approved Lupkynis (voclosporin) to treat active lupus nephritis, a serious complication of systemic lupus erythematosus (SLE) that is characterized by kidney inflammation. The approval is valid in all European Union (EU) member states, as well as Iceland, Liechtenstein, Norway, and Northern Ireland. Lupkynis received a similar…
DxTerity Diagnostics’ interferon-1 gene signature test, which can be used to help guide treatment decisions for people with systemic lupus erythematosus (SLE), is now available for use in all 50 U.S. states, the company has announced. “It is our mission to transform patient care with precision diagnostic tools that…
Active lupus nephritis — kidney inflammation as a result of lupus — is associated with a much higher risk of pregnancy complications, such as fetal loss and preeclampsia, according to a new analysis. The study also showed pregnancy complications are more common in Black women with lupus than among…
The Lupus Foundation of America and Lupus Canada are funding a new study to better understand the role of platelets in lupus. The Lupus Canada Catalyst Award, a one-year grant to fund research for a scientist in Canada studying the autoimmune disease, was awarded to Éric Boilard,…
The Lupus Research Alliance (LRA) has announced $9 million in grants — three awards each totaling $3 million — to fund new research projects that aim to better understand lupus and pave the way toward the development of better treatment strategies for the inflammatory autoimmune disease. The funding is…
Alpine Immune Sciences and Evotec announced the expansion of an agreement to manufacture ALPN-303, an experimental anti-inflammatory therapy that Alpine is developing for systemic lupus erythematosus (SLE) and other diseases driven by immune B-cells. Under the initial 2020 agreement, Evotec’s subsidiary Just-Evotec Biologics used its continuous manufacturing…
The U.S. Food and Drug Administration (FDA) has extended the use of Benlysta (belimumab), given on top of standard therapy, to treat children ages 5 to 17 with active lupus nephritis, a serious form of kidney inflammation caused by lupus. Benlysta is the first FDA-approved treatment for pediatric lupus…
Lower income is associated with a significantly higher risk of certain kidney diseases, including lupus nephritis, a new study found. The study, “Socioeconomic Position and Incidence of Glomerular Diseases,” was published in the Clinical Journal of American Society of Nephrology. How much money individuals have can…
An educational program done in small, local, and peer-led groups, called the Chronic Disease Self‐Management Program, was seen as helpful by African-American women with systemic lupus erythematosus (SLE), improving their diet, ability to exercise, and their adherence to treatment, a study suggests. The study, “Exploring…